Publications by authors named "Paul Slobbe"

Claim this Profile
D
Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts.
Paul Slobbe, Albert D Windhorst, Kevin Adamzek, Marije Bolijn, Robert C Schuit

Oncotarget· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents.
Paul Slobbe, Alex J Poot, Rianne Haumann, Robert C Schuit, Albert D Windhorst

Nucl Med Biol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.
Paul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, Egbert F Smit, Heiko G Niessen

EJNMMI Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors.
Paul Slobbe, Albert D Windhorst, Marijke Stigter-van Walsum, Robert C Schuit, Egbert F Smit

Nucl Med Biol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diastereoselective one-pot synthesis of tetrafunctionalized 2-imidazolines.
Guido V Janssen, Paul Slobbe, Maurice Mooijman, Art Kruithof, Andreas W Ehlers

J Org Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.
Paul Slobbe, Alex J Poot, Albert D Windhorst, Guus A M S van Dongen

Drug Discov Today· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of a selective fluorogenic Pup derived assay reagent for Dop, a potential drug target in Mycobacterium tuberculosis.
Remco Merkx, Kristin E Burns, Paul Slobbe, Farid El Oualid, Dris El Atmioui

Chembiochem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis